

Exclusion criteria included symptomatic brain metastasis, bone metastasis requiring radiation treatment, accumulation of plural fluid requiring treatment like drainage, continuous long-term treatment with non-steroidal anti-inflammatory agents, glucocorticoids, or morphine derivatives, serious complications or other active cancer, and those judged by the investigators to be inappropriate for the study. Patients who were pregnant, breast-feeding, or taking inadequate contraceptive precautions were also ineligible. Further, the protocol was amended during the course of the study to exclude patients with confirmed or suspected interstitial pneumonitis owing to the exacerbation of asymptomatic interstitial pneumonitis, identified by chest X-ray or computed tomographic (CT) scan before treatment, in three patients in an identical study, of whom two died [14]. The study protocol was approved by the institutional review board at each hospital, and written informed consent was obtained from all patients prior to participation.

Treatment

Amrubicin (Sumitomo Pharmaceuticals Co., Ltd, Osaka, Japan) was supplied as a freeze-dried powder in vials containing 20 mg each. It was reconstituted in 20 mL of physiological saline or 5% glucose solution and given by intravenous infusion at 45 mg/m²/day over 5 min on three consecutive days, with the cycle repeated every 3 weeks. A minimum of three cycles was undertaken except in the occurrence of disease progression, unacceptable toxicity or patient noncompliance.

Before treatment, all patients underwent medical history review, physical examination, hematology and serum biochemistry tests, urinalysis, electrocardiography (ECG), echocardiogram for left ventricular ejection fraction (LVEF), and baseline tumor measurements (e.g. chest radiography, CT scans, bone scintigraphy). Measurable and assessable lesions were evaluated within 2 weeks of the start of treatment, and ECG and LVEF within 1 month.

Laboratory variables were measured weekly as a rule, including complete differential blood cell counts, platelet counts, hematocrit, blood biochemistry, and urinalysis. Complete differential blood cell and platelet counts were obtained at least twice weekly when myelosuppression was observed. The ECG was measured with every treatment cycle, and the LVEF test every second cycle. Chest radiography and CT scans were carried out every cycle as a rule.

Subjective symptoms and objective signs were observed and recorded as required

Adjustment of dosage and schedule modification

Treatment was repeated when the WBC count recovered to $\geq 3,000/\mu\text{L}$ and the platelet count recovered to $\geq 100,000/$

μL . Treatment was delayed when recovery was incomplete until these values were reached, and withdrawn if they were not reached within 5 weeks. Dosage was maintained as in the previous course if the WBC nadir was $<1,000/\mu\text{L}$ for ≤ 3 days, or $\geq 1,000/\mu\text{L}$ and the platelet nadir was $\geq 50,000/\mu\text{L}$, and reduced by 5 mg/m²/day from the previous dosage if the respective values were $<1,000/\mu\text{L}$ for ≥ 4 days and/or $<50,000/\mu\text{L}$.

Response and toxicity evaluation

Response was assessed in accordance with the "Criteria for the evaluation of the clinical effects of solid cancer chemotherapy" of the Japan Society for Cancer Therapy [15], which are virtually identical to those of the World Health Organization [16], namely with a complete response (CR) defined as the disappearance of all lesions for a minimum of 4 weeks; a partial response (PR) as a 50% or greater decrease in the sum of the products of the diameters of the measurable lesions for a minimum period of 4 weeks and no new lesions; no change (NC) as a decrease in the tumor mass of less than 50% or any increase of less than 25%; and progression disease (PD) as an increase in the size of any measurable lesion by 25% or the appearance of new lesions.

Toxicity was graded based on the side effect record form of the Japan Society for Cancer Therapy criteria [15]. Toxicity items not included on the record form were recorded as present or absent without grading.

Table 1 Patient characteristics

Patient characteristics	No. of patients	Percent
No. of enrolled patients	62	
No. of eligible patients	60	
Age, years		
Median	65.5	
Range	41–75	
Gender		
Male	37	61.7
Female	23	38.3
Performance status (ECOG scale)		
0	8	13.3
1	41	68.3
2	11	18.3
Histology		
Squamous cell carcinoma	24	40.0
Adenocarcinoma	29	48.3
Large cell carcinoma	7	11.7
Stage		
IIIA	5	8.3
IIIB	14	23.3
IV	41	68.3

ECOG Eastern Cooperative Oncology Group

Table 2 Response to amrubicin

	No. of patients	Response (No. of patients)					Response rate, % [95%CI]
		CR	PR	NC	PD	NE	
Eligible patients	60	0	11	30	16	3	18.3 [9.5–30.4]
Histology:							
Squamous cell carcinoma	24	0	6	9	7	2	25.0
Adenocarcinoma	29	0	5	17	6	1	17.2
Large cell carcinoma	7	0	0	4	3	0	0
Stage							
IIIA	5	0	2	3	0	0	40.0
IIIB	14	0	3	7	3	1	21.4
IV	41	0	6	20	13	2	14.6
Performance status (ECOG):							
0	8	0	2	4	2	0	25.0
1	41	0	8	22	10	1	19.5
2	11	0	1	4	4	2	9.1

Abbreviations: CR, complete response; PR, partial response; NC, no change; PD, progressive disease; NE, not evaluated; ECOG, Eastern Cooperative Oncology Group

Statistical analyses

Primary endpoint was response rate. In this study, the number of patients was estimated as 60 to guarantee at least 10% response rate with a probability of 95% at 20% of expected response rate. Secondary endpoints were overall survival and safety. The time frame for overall survival was defined as the time from treatment until onset of the event. Kaplan–Meier life table was constructed for patient survival, 1-year survival, 2-year survival and median survival time [17]. All analyses were done using SAS, version 8.2 (SAS Institute Inc., Cary, North Carolina).

Results

Patient characteristics

Of 62 patients registered between April 1995 and September 1997 through 14 participating institutions in Japan, 60 patients were eligible and assessable for efficacy and 59 were assessable for safety (Table 1). Two patients were ineligible due to the protocol deviation in the inclusion criteria, not NSCLC in one patient and receiving prior chemotherapy in a second patient. Another patient was not safety-assessable due to a withdrawal of informed consent soon after the completion of first cycle treatment. By stage, 41 patients had stage IV disease, 14 had stage IIIB, and 5 had stage IIIA. Histologically, 29 patients had adenocarcinoma, 24 squamous cell carcinoma, and only 7 large cell carcinoma. Most patients had a good performance status (PS) of 0 or 1, but 11 (18.3%) had PS of 2. No patient had received any prior treatment, including radiotherapy.

Response and survival

Response among the 60 eligible patients was 11 PRs, giving an overall response rate of 18.3% (95% CI, 9.5 to 30.4%) (Table 2). Responders were 6 (25.0%) of 24 patients with squamous cell carcinoma and 5 (17.2%) of 29 with adenocarcinoma.

Regarding the overall survival curve, median survival time was 8.2 months (95% CI, 6.7 to 10.4 months), and 1- and 2-year survival rates were 34.9% and 7.6%, respectively (Fig. 2).




Fig. 2 Overall survival of patients with advanced non-small-cell lung cancer following treatment with amrubicin. Median survival time was 8.2 months (95% confidence interval, 6.7–10.4 months)

Table 3 Major treatment-related hematologic toxicity of amrubicin

Toxicity	No. of assessable patients	Toxicity grade					
		1	2	3	4	≥1	≥3
		(No. of patients)				Frequency (%)	
Anemia (hemoglobin)	59	16	17	16	2	86.4	30.5
Leukopenia	59	5	16	21	11	89.8	54.2
Neutropenia	59	0	7	12	34	89.8	78.0
Thrombocytopenia	59	12	3	9	8	54.2	28.8

Safety

Hematologic toxicities observed throughout the present clinical trial for which a causal relationship to amrubicin could not be denied are shown in Table 3. The most common was myelosuppression, particularly neutropenia, leukopenia and anemia (hemoglobin decrease) with frequencies of 89.8, 89.8 and 86.4%, respectively. Thrombocytopenia was somewhat lower frequent (54.2%). Among these, the incidence of grade 3 or 4 toxicity was 78.0% for neutropenia, 54.2% for leukopenia, 30.5% for anemia, and 28.8% for thrombocytopenia.

Although mild, non-hematologic toxicities included stomatitis, anorexia, nausea/vomiting, diarrhea, fever, alopecia, and AST/ALT elevation were each seen in more than 10% of the patients (Table 4). Grade 3/4 episodes were seen only for anorexia, nausea/vomiting, and alopecia with frequencies of each 1.7%. ECG abnormalities for which a relationship to amrubicin was unknown were seen in two patients, one with transient negative T and the second with ST depression, but were judged not to be clinically significant on review by a cardiologist. A decrease in LVEF for which a causal relation to amrubicin could not be denied

was seen in two patients, one with a decrease from 73% at base line to 53% after three cycles of treatment and in the second from 69 to 52% after two cycles. LVEF values fluctuate readily under the influence of various factors, and these changes are not particularly abnormal. Moreover, no accompanying changes in ECG or symptoms were seen, and thus the medical significance was not clear. However, given that amrubicin is an anthracycline derivative, like doxorubicin, the cardiotoxicity of which is well known, treatment was discontinued as precaution.

Discussion

This present study indicates that amrubicin is an active agent in the treatment of patients with NSCLC. Overall response rate was 18.3% (95% CI, 9.5 to 30.4%) and median survival time was 8.2 months (95% CI, 6.7 to 10.4 months). In an identical study, which included 61 patients, amrubicin achieved overall response rate of 27.9%, with 1 CR and 16 PRs, and median survival was 9.8 months [14]. Thus, the overall response rate for amrubicin in these two studies with an identical protocol was 23.1% (95% CI, 16.0 to 31.7%).

Table 4 Major treatment-related non-hematologic toxicities of amrubicin

Toxicity	No. of assessable patients	Toxicity grade					
		1	2	3	4	≥1	≥3
		(No. of patients)				Frequency (%)	
Stomatitis	59	7	2	0	0	15.3	0
Anorexia	59	20	20	1	– ^a	69.5	1.7
Nausea and vomiting	59	21	11	1	– ^a	55.9	1.7
Diarrhea	59	9	0	0	0	15.3	0
Fever	59	8	7	0	– ^a	25.4	0
Phlebitis	59	2	0	0	0	3.4	0
Alopecia	58	27	16	1	– ^a	75.9	1.7
Total bilirubin elevation	58	4	0	0	0	6.9	0
AST elevation	59	10	1	0	0	18.6	0
ALT elevation	59	9	4	0	0	22.0	0
ALP elevation	59	3	1	0	0	6.8	0
BUN elevation	59	4	0	0	0	6.8	0
Others ^b	LVEF decrease, 2/42 ^c ; ECG abnormality, 2/54 ^c						

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; BUN, blood urine nitrogen; LVEF, left ventricular ejection fraction; ECG, electrocardiogram

^a Toxicity grade not defined.

^b Toxicities not graded.

^c Ratio of number of reported patients to number of observed patients.

NSCLC is known to have poor sensitivity to chemotherapy [18–20], but the recent development of newer agents such as paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan has seen considerable improvements in therapeutic outcomes [21, 22], with response rates of more than 20% when used as single agents in previously untreated patients with advanced NSCLC. The present results indicate that amrubicin which is different from these newer agents in mode of action [9], namely the inhibition of topoisomerase II, is comparable to these newer agents in efficacy for NSCLC.

The major toxicity of amrubicin was hematologic, particularly neutropenia and leukopenia. In contrast, no febrile neutropenia was observed. Non-hematologic toxicity was relatively mild, with the only grade 3/4 episodes being seen for anorexia, nausea/vomiting, and alopecia with frequencies of each 1.7%. These safety results are supported by those from an identical study [14]. In that study, interstitial pneumonitis developed in three patients, of whom two died [14]. So the protocol was revised to exclude patients with confirmed or suspected interstitial pneumonitis. In the present study, interstitial pneumonitis was not seen.

Among cardiotoxicity, abnormalities in ECG and a decrease in LVEF were seen in two patients each. These changes were asymptomatic and did not overlap in the same patients. These findings suggest that unlike the case of cardiomyopathy caused by doxorubicin, the effect of amrubicin on cardiac function is neither serious nor definite. It is well known that doxorubicin experimentally and clinically causes cardiomyopathy which is cumulative toxicity caused by long-term treatment. In contrast, amrubicin on repeated administration did not cause cardiotoxicity or aggravate doxorubicin-induced cardiotoxicity in rabbits and dogs [7, 8]. Although cardiomyopathy has not been clinically observed to date, careful observation on the effects of amrubicin on the heart is required in further clinical studies, especially for patients on long-term treatment.

In conclusion, amrubicin showed promising activity against NSCLC in the present study. In a previous study, moreover, the combination of amrubicin and cisplatin demonstrated an impressive response rate and median survival time for extensive-stage SCLC (87.8% and 13.6 months, respectively) [23]. We are presently planning a phase II study of the combination of amrubicin and cisplatin for advanced NSCLC.

References

- Ishizumi K, Ohashi N, Tanno N (1987) Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. *J Org Chem* 52:4477–4485
- Tani N, Yabuki M, Komuro S, Kanamaru H (2005) Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. *Xenobiotica* 35:1121–1133
- Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. *Jpn J Cancer Res* 89:1067–1073
- Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. *Jpn J Cancer Res* 80:69–76
- Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. *Jpn J Cancer Res* 89:1055–1060
- Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M (1989) Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. *Jpn J Cancer Res* 80:77–82
- Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. *Invest New Drugs* 15:219–225
- Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in dogs. *Invest New Drugs* 16:121–128
- Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. *Jpn J Cancer Res* 89:1229–1238
- Hiraki S, Shinkai T, Furuse K, Fukuoka M, Ohnoshi T, Kimura I (1993) A phase II study of SM-5887, a novel 9-aminoanthracycline, for non-small-cell lung cancer. *Proceedings of the 18th international congress of chemotherapy* 866–867
- Sugiura T, Ariyoshi Y, Negoro S, Nakamura N, Ikegami H, Takada M, Yana T, Fukuoka M (2005) Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer. *Invest New Drugs* 23:331–337
- Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1999) Evaluation of amrubicin with a 5 day administration schedule in a mouse model. *Jpn J Cancer Chemother* 26:1305–1312
- Cortes EP, Takita H, Holland JF (1974) Adriamycin in advanced bronchogenic carcinoma. *Cancer* 34:518–525
- Sawa T, Yana T, Takada M, Sugiura T, Kudoh S, Kamei T, Isobe T, Yamamoto H, Yokota S, Katakami N, Tohda Y, Kawakami A, Nakanishi Y, Ariyoshi Y (2006) Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. *Invest New Drugs* 24:151–158
- Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. *J Jpn Soc Cancer Ther* 28:101–130
- World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48). World Health Organization, Geneva, Switzerland
- Kaplan WH, Meier P (1952) Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:583–612
- Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? *J Clin Oncol* 11:1866–1872
- Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Comier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP (1993) Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. *Lancet* 342:19–21
- Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. *BMJ* 311:899–909
- Ginsberg RJ, Vokes EE, Raben A (2001) Non-small cell lung cancer. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) *Cancer:*

- principles and practice of oncology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 925–983
22. Bunn PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. *Clin Cancer Res* 5:1087–1100
23. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N, Fukuoka M, Aritoshi Y (2005) Phase I–II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. *Ann Oncol* 16:430–436

Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

Takashi Yana · Shunichi Negoro · Minoru Takada · Soichiro Yokota ·
Yoshiki Takada · Takahiko Sugiura · Hidehiko Yamamoto · Toshiyuki Sawa ·
Masaaki Kawahara · Nobuyuki Katakami · Yutaka Ariyoshi · Masahiro Fukuoka

Received: 28 January 2005 / Accepted: 5 September 2006 / Published online: 13 October 2006
© Springer Science + Business Media, LLC 2006

Summary Purpose: To evaluate the efficacy and safety of amrubicin, (+)-(7*S*, 9*S*)-9-acetyl-9-amino-7-[(2-deoxy- β -D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride, in previously untreated patients with extensive-disease small cell lung cancer (SCLC).

Patients and methods: A total of 35 previously untreated patients with extensive-disease SCLC were entered into the study. Amrubicin was given by daily intravenous infusion at 45 mg/m²/day for 3 consecutive days, every 3 weeks. Unless there was tumor regression of 25% or greater after the first cycle, or 50% or greater after the second cycle, treatment was switched to salvage chemotherapy in combination

with etoposide (100 mg/m², days 1, 2, and 3) and cisplatin (80 mg/m², day 1).

Results: Of the 35 patients entered, 33 were eligible and assessable for efficacy and toxicity. Of the 33 patients, 3 (9.1%) had a complete response (95% confidence interval [CI], 1.9–24.3%) and 22 had a partial response, for an overall response rate of 75.8% (95% CI, 57.7–88.9%). Median survival time was 11.7 months (95% CI, 9.9–15.3 months), and 1-year and 2-year survival rates were 48.5% and 20.2%, respectively. The most common toxicity was hematologic. Non-hematologic toxicity of grade 3 or 4 was only seen in 3 patients with anorexia (9.1%) and 1 patient with alopecia (3.0%). Salvage chemotherapy was administered to only 6 patients.

T. Yana · M. Takada
Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Habikino

S. Negoro
Department of Clinical Oncology, Osaka City General Hospital, Osaka

S. Yokota
Department of Internal Medicine, National Toneyama Hospital for Chest Diseases, Toyonaka

Y. Takada
Department of Radiology, Hyogo Medical Center for Adults, Akashi

T. Sugiura
Department of Internal Medicine, Aichi Cancer Center Hospital, Nagoya

H. Yamamoto
Department of Internal Medicine, Aso Iizuka Hospital, Iizuka

T. Sawa
Division of Respiratory Medicine, Gifu Municipal Hospital, Gifu

M. Kawahara
Department of Internal Medicine, National Kinki Central Hospital for Chest Disease, Sakai

N. Katakami
Division of Pulmonary Medicine, Kobe City General Hospital, Kobe

Y. Ariyoshi
Department of Internal Medicine, Prefectural Aichi Hospital, Okazaki

M. Fukuoka
Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Japan

T. Yana (✉)
Division of Respiratory Medicine, KKR Otemae Hospital, 1-5-34, Otemae, Chuo-ku, Osaka 540-0008, Japan
e-mail: t-yana@otemae.gr.jp

Conclusion: Amrubicin was active for extensive-disease SCLC with acceptable toxicity. Further studies in combination with other agents for SCLC are warranted.

Keywords Amrubicin · Small cell lung cancer · Anthracycline · Previously untreated patients · Phase II study


Introduction

Small cell lung cancer (SCLC) is a major cause of cancer deaths and accounts for 15 to 20% of all lung cancers [1]. Although this cancer is initially highly responsive to chemotherapy, the vast majority of patients will ultimately relapse and die of recurrent disease within 2 years [2]. Recently, combination chemotherapy with irinotecan and cisplatin for extensive-disease SCLC produced more survival benefit than etoposide and cisplatin, the worldwide standard regimen since 1981 [3, 4]. Median survival time and 2-year survival rate of the standard regimen is 12.8 months and 19.5%, respectively. Clearly, new and more effective agents against SCLC are needed.

Amrubicin is a totally synthetic 9-aminoanthracycline, (+)-(7*S*, 9*S*)-9-acetyl-9-amino-7-[(2-deoxy-β-*D*-erythro-pentopyranosyl)oxy]-7, 8, 9, 10-tetrahydro-6, 11-dihydroxy-5,12-naphthacenedione hydrochloride, with a chemical structure similar to that of doxorubicin (Fig. 1) [5]. Amrubicin showed more potent antitumor activity than doxorubicin in several human tumor xenografts implanted in nude mice [6]. Acute toxicity of amrubicin is qualitatively similar to that of doxorubicin [7], however, amrubicin shows almost no delayed toxicity (e.g. cardiotoxicity) [8, 9].

Amrubicin is converted to an active metabolite, amrubicinol, by reduction of its C-13 ketone group to a hydroxy group. *In vitro* cytotoxic activity of amrubicinol was almost equipotent to that of doxorubicin and 20 to 220 times more potent than that of its parent compound, amrubicin [10]. Amrubicinol is considered to be closely associated with the efficacy and toxicity of amrubicin [11].

Fig. 1 Chemical structures of amrubicin and doxorubicin



Despite their similarity in chemical structure, amrubicin has a different mode of action to doxorubicin [12]. Amrubicin and its active metabolite, amrubicinol, are inhibitors of DNA topoisomerase II. Amrubicin and amrubicinol exert cytotoxic effects by stabilizing topoisomerase II-mediated cleavable complexes, while doxorubicin does not inhibit this step of the catalytic cycle of topoisomerase II at concentrations for which it demonstrates cytotoxicity. Doxorubicin is a potent DNA intercalator, and its cytotoxicity is thought to be mainly due to this. Amrubicin and amrubicinol are about one-tenth weaker DNA intercalators than doxorubicin. Therefore, they are similar to etoposide in terms of inhibition of topoisomerase II by stabilizing the cleavable complexes, although etoposide does not show any DNA intercalating activity.

In a phase I–II study in patients with non-small cell lung cancer, amrubicin was administered as a 5-min intravenous infusion for 3 consecutive days [13]. The maximum tolerated dose (MTD) was 50 mg/m²/day and the dose-limiting toxicities were leukopenia, neutropenia, thrombocytopenia, and gastrointestinal complications. The recommended dose for the phase II study was 45 mg/m²/day for 3 consecutive days every 3 weeks.

Based on these experimental data and preliminary clinical reports indicating that amrubicin may be active against lung cancer, the West Japan Thoracic Oncology Group (WJTOG) evaluated it for use in SCLC. The WJTOG conducted a phase II study in previously untreated extensive-disease SCLC patients as a first-line therapy. Salvage chemotherapy with etoposide and cisplatin and an early cessation rule were set in place as precautionary measures.

Patients and methods

Eligibility criteria

Eligibility criteria included histologically or cytologically proven small cell lung cancer with extensive-disease defined as distant metastasis and/or disease involving the

contralateral hilar lymph nodes; no prior treatment; life expectancy of at least 2 months; the Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; at least one bidimensionally measurable lesion; age less than 80; adequate organ function, such as white blood cell (WBC) count of $4000 \times 10^6/L$ or greater, hemoglobin level 10 g/dL or greater, platelet count $100 \times 10^9/L$ or greater, AST and ALT less than 100 IU/L, bilirubin level 1.5 mg/dL or less, creatinine concentration 1.2 mg/dL or less, electrocardiogram (ECG) findings within normal range, and left ventricular ejection fraction (LVEF) of echocardiogram 60% or greater. All patients gave written informed consent. Ineligibility criteria were: brain or bone metastases requiring radiation; continuous long-term treatment with non-steroidal anti-inflammatory drugs and glucocorticoids; pulmonary fibrosis; serious complications and other active malignancy; or pregnant or nursing subjects.

This study was approved by the institutional review boards at each participating center.

Study design

Amrubicin (Sumitomo Pharmaceuticals Co., Ltd, Osaka, Japan) was dissolved in 20 mL normal saline and administered once intravenously as a 5-min infusion at a dose of $45 \text{ mg/m}^2/\text{day}$ on days 1 to 3, every 3 weeks.

Before treatment, all patients underwent a medical history, physical examination, hematology and serum biochemistry tests, urinalysis, ECG, LVEF, and baseline tumor measurements (chest radiography, CT scans, bone scintigraphy, and other measurements as appropriate). All measurable and assessable lesions were evaluated within 2 weeks before treatment. ECG and LVEF were undertaken within 1 month before treatment.

Complete and differential blood cell counts, platelet counts, hematocrit analysis, biochemical analysis including AST, ALT, alkaline phosphatase, LDH, total bilirubin, BUN, creatinine, serum bilirubin, albumin, total protein, and electrolyte levels (Na, K, Cl, and Ca), and urinalysis (including protein, glucose, urobilinogen, and occult blood) were performed weekly as a rule. When severe myelosuppression was observed, complete and differential blood cell counts plus platelet counts were performed 2 times or more per week. ECG was undertaken every treatment cycle and LVEF every other cycle. Chest radiography and CT scans were carried out every cycle as a rule.

Subjective and objective symptoms were observed and recorded as appropriate.

Dose modifications were made according to WBC and platelet counts. If the WBC count nadir was lower than $1,000 \times 10^6/L$ for 4 days or longer and/or the platelet count nadir was lower than $50 \times 10^9/L$, a dose reduction of 5 mg

was stipulated in the subsequent treatment course. Treatment was postponed until the WBC and platelet counts recovered to $\geq 3,000 \times 10^6/L$ and $\geq 100 \times 10^9/L$, respectively.

In patients who demonstrated tumor regression of 25% or greater after the first course of chemotherapy, amrubicin treatment was continued. After the second course, patients had to have achieved tumor regression of 50% or greater to continue to receive the drug up to a maximum of 6 courses. Treatment of combination chemotherapy with etoposide (100 mg/m^2 on days 1, 2, and 3) and cisplatin (80 mg/m^2 on day 1) was recommended for patients who failed to fulfill any of the above criteria.

Evaluation of response and toxicity

Response was assessed according to the "Criteria for the evaluation of the clinical effects of solid cancer chemotherapy" of the Japan Society for Cancer Therapy [14], which are virtually identical to those of the World Health Organization [15]. A complete response (CR) was defined as disappearance of all lesions for a minimum of 4 weeks. A partial response (PR) was defined as a 50% or greater decrease in the sum of the products of the diameters of measurable lesions for a minimum period of 4 weeks and no new lesions. No change (NC) was defined as a decrease in the tumor mass of less than 25% or any increase of less than 25%. Progressive disease (PD) was defined as an increase in the size of any measurable lesion by 25% or greater or the appearance of new lesions.

Toxicity grading was recorded based on the side effect record form in the "Criteria for the evaluation of the clinical effects of solid cancer chemotherapy" of the Japan Society for Cancer Therapy [14].

Statistical analyses

The estimated sample size was 30 to guarantee that the lower limits of 95% confidence interval would be at least 20% at 40% of expected response rate. An early cessation rule was in place to terminate the study if at least 4 responses had not been seen among 15 patients evaluated. Median overall survival was estimated using the product-limit (Kaplan-Meier) method [16].

Results

Patient characteristics

Of 35 patients entered into this study between May 1995 and January 1997, 33 patients were eligible and assessable for efficacy and toxicity. There were 2 ineligible patients because of serious complications before treatment (cardiac

Table 1 Patient characteristics

Patient characteristics	No. of patients (<i>N</i> = 33)	%
Age (years)		
Median	66	
Range	42–78	
Sex		
Male	29	87.9
Female	4	12.1
Performance status (ECOG)		
0	5	15.2
1	26	78.8
2	2	6.1
Stage		
IIIB	1	3.0
IV	32	97.0
Prior therapy		
No	33	100

ECOG: Eastern Cooperative Oncology Group.

failure and aggravation of hepatitis, respectively), and they did not receive amrubicin. Characteristics of the 33 eligible patients are shown in Table 1. Of the 33 patients, 13 (39%) were 70 years of age or older, 88% were male, and 94% had an ECOG performance status of 0 or 1.

Efficacy

Response to amrubicin is shown in Table 2. The early cessation rule was not imposed to terminate the study, as 10 responses were seen after 15 patients were enrolled. Of 33

patients, 3 achieved a complete response, giving a CR rate of 9.1% (95% CI, 1.9–24.3%), and 22 a partial response, for an overall response rate of 75.8% (95% CI, 57.7–88.9%). Of 7 patients, 6 experiencing no change under amrubicin treatment were switched to salvage chemotherapy. Of these, 2 had partial responses and the others had no change.

The overall survival curve is shown in Fig. 2. Median survival time was 11.7 months (95% CI, 9.9–15.3 months), and 1-year and 2-year survival rates were 47.7% (95% CI, 31.4–65.5%) and 20.2% (95% CI, 6.4–34.4%), respectively.

Toxicity

The major observed toxicity was hematologic, as shown in Table 3. All patients experienced leukopenia and neutropenia. Grade 3 or 4 leukopenia occurred in 51.5% of patients and grade 3 or 4 neutropenia in 84.8%. Anemia and thrombocytopenia were observed in 78.8% and 39.4% of patients, respectively, both with a frequency of grade 3 or 4 of 21.2%. Despite the severe hematologic toxicity of amrubicin, there was no febrile neutropenia or treatment-related death during the entire treatment of 33 patients. Granulocyte colony-stimulating factor (G-CSF) was used in 55 (40%) of a total of 136 cycles, in 13 patients (39%). Most hematologic toxicity in this trial was well-controlled without dose reduction: 88% of the total treatment cycles were delivered at the planned dosage of amrubicin, 45 mg/m²/day.

Non-hematologic toxicities observed in more than 10% of patients were anorexia (54.5%), nausea and vomiting

Table 2 Response to amrubicin

No. of assessable patients	Response (No. of patients)				CR rate, % (95% CI)	Response rate, % (95% CI)
	CR	PR	NC	PD		
33	3	22	7	1	9.1 (1.9–24.3)	75.8 (57.7–88.9)

CR: complete response; PR: partial response; NC: no change; PD: progressive disease; 95% CI: 95% confidence interval.

Fig. 2 Overall survival of patients with extensive-disease small cell lung cancer treated with amrubicin. MST: median survival time; 95% CI: 95% confidence interval




Table 3 Main treatment-related toxicity of amrubicin

Toxicity	No. of assessable patients	Toxicity grade others				Frequency (%)	
		1	2	3 (No. of patients)	4	≥ 1	≥ 3
Hematologic toxicity							
Anemia (hemoglobin)	33	12	7	6	1	78.8	21.2
Leukopenia	33	5	11	13	4	100	51.5
Neutropenia	33	1	4	14	14	100	84.8
Thrombocytopenia	33	3	3	1	6	39.4	21.2
Non-hematologic toxicity							
Stomatitis	33	2	1	0	0	9.1	0
Anorexia	33	12	3	3	– ^a	54.5	9.1
Nausea and vomiting	33	12	7	0	– ^a	57.6	0
Diarrhea	33	6	0	0	0	18.2	0
Fever	33	3	7	0	0	30.3	0
Phlebitis	33	1	1	0	0	6.1	0
Alopecia	33	11	8	1	– ^a	60.6	3.0
Total bilirubin elevation	33	1	1	0	0	6.1	0
AST elevation	33	5	0	0	0	15.2	0
ALT elevation	33	8	1	0	0	27.3	0
ALP elevation	33	1	0	0	0	3.0	0
BUN elevation	33	2	0	0	0	6.1	0
Others ^b	Headache, 1/33 ^c ; Rash, 1/33; Constipation, 1/33; Interstitial pneumonia, 1/33; Rhinorrhagia, 1/33; ECG abnormality, 3/32						

AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; BUN: blood urine nitrogen; ECG: electrocardiogram.

^aToxicity grade was not defined for these toxicities.

^bToxicities which were not graded.

^cProportion of number of reported patients to number of observed patients.

(57.6%), diarrhea (18.2%), fever (30.3%), alopecia (60.6%), AST increase (15.2%), and ALT increase (27.3%). Most of these were mild (\leq grade 2), with only 3 patients (9.1%) experiencing grade 3 anorexia and 1 patient grade 3 alopecia (3.0%). A single patient developed interstitial pneumonia after the second cycle of treatment; however, it was reversibly recovered by steroid therapy and cessation of amrubicin treatment. ECG abnormality was observed in 3 patients (9.4%; supraventricular extrasystole, prolonged QT interval, and T wave flattening in 1 patient each), which did not need any treatment. No LVEF decrease was observed.

Discussion

Results of this phase II study demonstrate that amrubicin is an extremely active agent against extensive-disease SCLC. The complete response rate was 9.1% (95% CI, 1.9–24.3%), overall response rate 75.8% (95% CI, 57.7–88.9%), and median survival time 11.7 months (95% CI, 9.9–15.3 months). These results are comparable or even superior to those of the standard combination regimen of cisplatin and etoposide, used as the gold standard of extensive-disease SCLC

therapy since 1981 and remaining unchanged over the last 2 decades [4].

SCLC is sensitive to cytotoxic anticancer agents. Of anticancer drugs developed before 1990, a number of agents with response rates of 20% or greater for SCLC were listed as active drugs [17]. Of these drugs, etoposide, cisplatin, carboplatin, doxorubicin, cyclophosphamide, and vincristine, are still currently used as important constituents of combination regimens in the treatment of SCLC. In addition, several drugs with significant activity for SCLC have been developed since 1990. Irinotecan showed a response rate of 33% to 47% even in previously treated patients who are generally less sensitive to chemotherapy [18, 19]. Recently a new combination regimen of irinotecan plus cisplatin was demonstrated to be significantly superior to standard regimen of etoposide plus cisplatin in median survival time (12.8 months vs. 9.4 months, $P = 0.002$) [3]. In addition, topotecan, paclitaxel, docetaxel, and gemcitabine are reported to have response rates of 26% to 41% for extensive-disease SCLC patients without previous treatment [20–24]. Compared to these agents, amrubicin demonstrated a much higher response rate (75.8%) in this study, indicating it is a promising novel agent with potential to overcome the therapeutic plateau of SCLC.

The major toxicity of amrubicin was hematologic. Grade 3 or 4 leukopenia was frequently observed in 51.5% of patients and grade 3 or 4 neutropenia in 84.8% of patients. Despite such severe hematologic toxicity, 88% of the total treatment cycles could be delivered without dose reduction and non-hematologic toxicities were mild. Although anorexia (54.5%) and nausea and vomiting (57.6%) were frequently observed, there were no episodes of grade 3 or 4 toxicity, except for 3 patients (9.1%) with grade 3 anorexia and 1 patient (3.0%) with grade 3 alopecia. A single patient developed interstitial pneumonia; however, this was reversible with steroid therapy. ECG abnormalities were observed in 3 patients, but they were each reviewed by a medical cardiologist and judged not to be clinically significant. No LVEF decrease was observed. Results show that the toxic profiles of amrubicin are acceptable and favorable in the treatment of extensive-disease SCLC, although due to its hematologic toxicity, in particular neutropenia, G-CSF support is needed.

In conclusion, amrubicin is a very active and promising agent with acceptable toxicity for patients with SCLC. Further studies are warranted in combination with other agents for this disease.

References

- Murren J, Glatstein E, Pass H (2001) Small cell lung cancer. In: DeVita VTJ, Hellman S, Rosenberg SA (eds) *Cancer: principles and practice of oncology*, 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 983–1018
- Aisner J (1996) Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. *J Clin Oncol* 14:658–665
- Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, for the Japan Clinical Oncology Group (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med* 346:85–91
- Aisner J, Alberto P, Bitran J, Comis R, Daniels J, Hansen H, Ikegami H, Smyth J (1983) Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. *Cancer Treat Rep* 67:37–43
- Ishizumi K, Ohashi N, Tanno N (1987) Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. *J Org Chem* 52:4477–4485
- Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. *Jpn J Cancer Res* 80:69–76
- Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M (1989) Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. *Jpn J Cancer Res* 80:77–82
- Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. *Invest New Drugs* 15:219–225
- Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. *Invest New Drugs* 16:121–128
- Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. *Jpn J Cancer Res* 89:1067–1073
- Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) *In vivo* efficacy and tumor-selective metabolism of amrubicin to its active metabolite. *Jpn J Cancer Res* 89:1055–1060
- Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. *Jpn J Cancer Res* 89:1229–1238
- Negoro S, Fukuoka M, Nakamura S, Ikegami H, Sugiura T, Ariyoshi Y, Takada M, Yana T, Ogawa M (1995) Phase I–II study of amrubicin (SM-5887), a novel 9-aminoanthracycline, by iv administration for 3 consecutive days in patients with advanced non-small-cell lung cancer (abstract). *Proc Am Soc Clin Oncol* 14:361
- Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. *J Jpn Soc Cancer Ther* 28:101–130
- World Health Organization (1979) Handbook for reporting results of cancer treatment (WHO Offset Publication No. 48). World Health Organization, Geneva, Switzerland
- Kaplan WII, Meier P (1952) Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:583–612
- Grant SC, Gralla RJ, Kris MG, Orazem J, Kitis EA (1992) Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. *J Clin Oncol* 10:484–498
- Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, Motomiya M, Kurita Y, Hasegawa K, Kuriyama T, Nishiwaki Y, Ogawa M, Nakao I, Saijo N, Obo K, Furue H, Ariyoshi Y, Shimokata K, Furuse K, Nakajima S, Irie K, Kimura I, Ogura T, Fujii M, Hara N, Hara Y, Nakano N, Araki J, Miyata Y, Taguchi T (1991) A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. *Jpn J Cancer Chemother* 18:1013–1019
- Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. *J Clin Oncol* 10:1225–1229
- Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D (1996) Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. *J Clin Oncol* 14:2345–2352
- Etinger DS, Finkelstein DM, Sarma RP, Johnson DH (1995) Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. *J Clin Oncol* 13:1430–1435
- Kirschling R, Jung S, Jett J (1994) A phase II study of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (SCLC) (abstract). *Proc Am Soc Clin Oncol* 13:326
- Hesketh P, Crowley J, Burris HA 3rd, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livingston RB, Gandara DR (1999) Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. *Cancer J Sci Am* 5:237–241
- Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P, Wong D (1994) Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. *Ann Oncol* 5:283–285

Phase II Study of Paclitaxel and Irinotecan Chemotherapy in Patients With Advanced Nonsmall Cell Lung Cancer

Fumihiko Oshita, MD, Haruhiro Saito, MD, Kouzo Yamada, MD, and Kazumasa Noda, MD

Objectives: We conducted a phase II study of combination chemotherapy with paclitaxel (Pac) and irinotecan (CPT) to determine the qualitative and quantitative toxicities and efficacy of the combination against advanced nonsmall cell lung cancer (NSCLC).

Patients and Methods: Patients with stage IIIB or IV NSCLC were treated with CPT at 60 mg/m² and Pac at 160 mg/m² every 2 weeks.

Results: Between May 2002 and July 2004, 39 of registered 46 patients received 4 to 6 cycles of chemotherapy, and 7 patients discontinued treatment because of disease progression in 5 patients and grade 2 pneumonitis in 2 patients. Grade 3 anemia, leukopenia, neutropenia, and elevation of bilirubin occurred in 4.0%, 0.5%, 1.0%, and 0.5%, respectively. Twenty-one patients responded, and the overall response rate was 45.6%. The median survival time was 355 days and the 1-year survival rate was 47.8%.

Conclusion: Pac plus CPT was efficacious and safe in NSCLC.

Key Words: paclitaxel, irinotecan, nonsmall cell, lung cancer

(*Am J Clin Oncol* 2007;30: 358-360)

Current chemotherapy regimens for metastatic nonsmall cell lung cancer (NSCLC) are not particularly effective, and the disease cannot be cured even with the most effective chemotherapy. Current international guidelines recommend the use of platinum-based chemotherapy for patients with advanced NSCLC,¹ and the use of doublets including platinum plus a third-generation agent has been widely accepted for patients with a good performance status. A meta-analysis of the published literature clearly showed the superiority of platinum-containing regimens in terms of objective response rate, and this superiority was found throughout the subgroup analyses performed.² The study results also confirmed that platinum-based therapy is generally associated with higher toxicity, particularly nausea and vomiting, hematologic toxicity, and nephrotoxicity. Nevertheless, platinum-based regimens can be administered as safely as nonplatinum therapies

when patients are selected correctly. However, this study did not include every combination of nonplatinum drugs, and it is necessary to examine every such new combination for efficacy and toxicity.

Combined analysis of two randomized phase III studies demonstrated that irinotecan (CPT) combined with cisplatin significantly improves survival compared with vindesine and cisplatin in patients with advanced NSCLC.³ In Japan, CPT is considered a key drug against NSCLC. Preclinical studies that have evaluated combinations of a camptothecin with a taxane have yielded promising results, and several studies have demonstrated an additive or synergistic interaction between camptothecin and taxanes.⁴ Our previous phase I study of a Pac and CPT combination showed that pneumonitis was the dose-limiting toxicity and led to a recommendation of Pac 160 mg/m² and CPT 60 mg/m² every 2 weeks for further study.⁵ This study also demonstrated an objective response rate of 58.3% and a 1-year survival rate of 54.2%. Accordingly, we expected the combination of Pac and CPT to display high activity against NSCLC and designed a phase II study to determine the efficacy and toxicities.

PATIENTS AND METHODS

The Institutional Review Board of Kanagawa Cancer Center reviewed and approved this study prior to commencement.

Patients

Patients with histologically or cytologically confirmed NSCLC were registered. Eligibility criteria were: clinical stage IIIB or IV, an expected survival of at least 12 weeks, age <70 years, Eastern Cooperative Oncology Group PS score ≤1, leukocyte count ≥4000/μL, hemoglobin ≥10 g/dL, platelet count ≥100,000/μL, total serum bilirubin ≤1.5 mg/dL, aspartate aminotransferase and alanine aminotransferase ≤90 IU/L, and serum creatinine ≤1.5 mg/dL. Patients who had experienced postoperative recurrence were eligible for this study, but a 4 or more week rest period was required after surgery. Patients who had received chemotherapy or radiotherapy were excluded from this study. Written informed consent was obtained from every patient.

Chemotherapy

All patients without disease progression were treated every 2 weeks for a total of 4 courses of chemotherapy. CPT was administered at a dose of 60 mg/m² on day 1. Pac was administered at a dose of 160 mg/m² on day 1. Premedication

From the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.

Supported in part by the Kanagawa Prefectural Hospitals Cancer Research Fund and Kanagawa Health Foundation.

Reprints: Fumihiko Oshita, MD, Department of Thoracic Oncology, Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan. E-mail: foshita@kcch.jp.

Copyright © 2007 by Lippincott Williams & Wilkins
ISSN: 0277-3732/07/3004-0358

DOI: 10.1097/O1.coc.0000258091.25459.d1

consisting of 20 mg dexamethasone and 50 mg ranitidine was infused. A 50-mg oral dose of diphenhydramine was also administered. Prophylactic G-CSF, 50 $\mu\text{g}/\text{m}^2$ per day or 2 $\mu\text{g}/\text{kg}$ per day, was administered subcutaneously on days 6 to 10. Patients were given a 5-HT₃ antagonist intravenously. Subsequent courses of chemotherapy were started when patients satisfied the organ function criteria: leukocyte count $\geq 3000/\mu\text{L}$, neutrophil count $\geq 1500/\mu\text{L}$, platelet count $\geq 75,000/\mu\text{L}$, and less than grade 1 nonhematologic toxicities, except alopecia. Grade 3 nausea and vomiting did not preclude subsequent courses of chemotherapy. Chemotherapy was repeated for a maximum of 6 courses unless the disease progressed, but it was stopped if the tumor response was judged to be NC after 4 courses. Tumor response was evaluated according to RECIST criteria.⁶ Toxicities were evaluated according to the NCI-CTC (version 2) criteria.⁷

Study Design

We chose a 50% response rate as a desirable target level and a 30% response rate as uninteresting. The study design had power in excess of 90% and less than 10% error; therefore, 22 assessable patients in the first step and 24 in the second step were required according to the optimal design of Simon.⁸ We decided to stop the study if there were fewer than 8 responders in the first step. The regimen was defined as active if there were 18 or more responders out of the total of 46 patients. Overall survival was estimated by the method of Kaplan and Meier.

RESULTS

Between May 2002 and July 2004, 46 patients were registered in the phase II study (Table 1). A total of 22 patients were registered for assessment of response in the first stage. Nine of 22 patients in the first stage responded and 24 patients were registered in the second stage. A total of 198 cycles was administered to 46 patients. Thirty-nine patients received 4 to 6 cycles of chemotherapy, except for 7 patients who discontinued treatment in the first or second cycles because of disease progression in 5 patients and grade 2 pneumonitis with pulmonary infiltration in 2 patients. Adverse effects and events are summarized in Table 2. Grade 3 anemia, leukopenia, neutropenia, and elevation of bilirubin occurred in 4.0%, 0.5%, 1.0%, and 0.5%, respectively. There were no grade 4 toxicities.

Twenty-one of 46 patients achieved partial response, 18 no change, 6 progressive disease, and 1 not evaluated, and the overall response rate was 45.6% in phase II study. The median duration of partial response was 154 days (range, 76–380 days). The median survival time was 355 days and the 1-year survival rate was 47.8% (Table 3). The outcome in 70 patients including those from the phase I study (5) demonstrated that 1 patient achieved complete response, 34 PR, and the overall response rate was 50.0%. The median survival time was 361 days and the 1-year survival rate was 50.0%.

DISCUSSION

The objective response rate of 50.0% and 1-year survival rate of 50.0% with our nonplatinum Pac and CPT

TABLE 1. Patient Characteristics

Characteristic	Value
Total	46
Age (years)	
Median	61
Range	43–69
Gender (no. patients)	
Male	29
Female	17
Performance status (ECOG) (no. patients)	
0	12
1	34
Clinical stage (no. patients)	
IIIB	6
IV	34
Postoperative recurrence	6
Histology (no. patients)	
Adenocarcinoma	36
Others	10
No. metastatic organs (no. patients)	
1	27
≥ 2	13
Brain metastasis (no. patients)	8

TABLE 2. Adverse Effects and Events

Toxicity	NCI-CTC Grade (No. Cycles)					% \geq Grade 3
	0	1	2	3	4	
Hemoglobin	29	137	24	8	0	4.0
Leukocyte	162	23	12	1	0	0.5
Neutrophil	167	19	10	2	0	1.0
Platelets	188	10	0	0	0	—
Bilirubin	165	22	10	1	0	0.5
Creatinine	192	6	0	0	0	—
SGOT	146	51	1	0	0	—
SGPT	135	55	8	0	0	—
Infection	194	3	1	0	0	—
Nausea/vomiting	143	51	4	0	0	—
Diarrhea	165	31	2	0	0	—
Myalgia	97	76	25	0	0	—
Arthralgia	110	64	24	0	0	—
Neuropathy	107	76	15	0	0	—
Fever	183	14	1	0	0	—
Allergic reaction	195	3	0	0	0	—
Alopecia	95	79	24	0	0	—
Pneumonitis	196	0	2	0	0	—
Hypotension	193	5	0	0	0	—
Arrhythmia	194	4	0	0	0	—

NCI-CTC, National Cancer Institute-Common Toxicity Criteria (version 2).

regimen in 70 patients in phase I and phase II studies are somewhat better than in a large phase III trial of 4 platinum-based chemotherapy regimens, which showed response rates of 17% to 22% and 1-year survival rates of 31% to 34%.⁹ The

TABLE 3. Therapeutic Outcome in Phase II Study

Response	No. Patients
Complete response	0
Partial response	21
No change	18
Progressive disease	6
Not evaluated	1
Response rate (%)	45.6
Median survival time (days)	355
% of 1-year survivor	47.8

antitumor activity of the Pac and CPT combination is thought to be attributable to a synergistic action between these drugs. A possible mechanism of the synergy is a drug-drug interaction, such as that shown in a pharmacokinetic study that demonstrated elevation of the AUC of CPT and SN-38 by Pac infusion.¹⁰ Although we acknowledge the possibility that Pac and CPT might affect each other's pharmacokinetics, increasing their activity against NSCLC, we also considered that another possible mechanism for this high activity of the Pac and CPT combination might be related to influx and efflux in the cell system. The combination of Pac and SN-38 down-regulates the level of multidrug resistance-associated protein, which may be an efflux pump for cisplatin, in ovarian cancer cell lines, suggesting that this combination will overcome drug resistance.¹¹

The combination of Pac and CPT also appears useful in that little toxicity was observed in this study. No patients experienced grade 4 toxicities. All patients, except the 5 patients who developed disease progression during treatment and the 2 patients who experienced grade 2 pneumonitis with pulmonary infiltration, were able to receive 4 to 6 cycles of this therapy. The pneumonitis was thought to be attributable to a booster effect of an allergic reaction when 180 mg/m² or higher of Pac was combined with CPT in the phase I study, but no patients experienced pneumonitis during cycles 2 to 6 of chemotherapy in this phase II study. Therefore, pneumonitis was seen at a frequency similar to that in other combi-

nation chemotherapies. Neutropenia was mild because of the prophylactic use of G-CSF in this study. We used G-CSF when monocytopenia less than 150/ μ L appeared in the phase I study,⁵ and most patients received G-CSF for 5 days starting on days 5, 6, or 7. Consequently, G-CSF was given routinely for 5 days from day 5 to day 9 in every cycle in the present study. This less toxic regimen may be helpful in the treatment of high-risk patients, such as the elderly or those with poor performance status or moderately severe complications.

REFERENCES

1. American Society of Clinical Oncology. Treatment of unresectable non-small cell lung cancer guideline: update 2003. *J Clin Oncol*. 2004; 22:330-353.
2. D'Addario G, Pintile M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. *J Clin Oncol*. 2005;23: 2926-2936.
3. Negoro S, Masuda N, Takada Y, et al. Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small cell lung cancer. *Br J Cancer*. 2003;88:335-341.
4. Fukuda M, Nishio K, Shiraishi J, et al. Effects of combinations of CPT-11, paclitaxel and other anticancer agents on human small cell lung cancer cells. *Cell Pharmacol*. 1996;3:1-6.
5. Yamada K, Ikehara M, Tanaka G, et al. Dose escalation study of paclitaxel in combination with fixed dose irinotecan in patients with advanced non-small cell lung cancer (JCOG9807). *Oncology*. 2004;66: 94-100.
6. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst*. 2000;92:205-216.
7. NCI-CTC, version 3, National Cancer Institute: Common Toxicity Criteria, version 2. <http://ctep.cancer.gov/reporting/CTC-3.html>.
8. Simon R. Optimal two-stage designs for phase II clinical trial. *Control Clin Trial*. 1989;10:1-10.
9. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*. 2002;346:92-98.
10. Yamamoto N, Negoro S, Chikazawa H, et al. Pharmacokinetic interaction of the combination of paclitaxel and irinotecan in vivo and clinical study [Abstract]. *Proc Am Soc Clin Oncol*. 1999;18:187.
11. Komuro Y, Udagawa Y, Susumu N, et al. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin. *Jpn J Cancer Res*. 2001;92: 1242-1250.

Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy

Kiyoshi Mori · Yukari Kamiyama · Tetsuro Kondo ·
Yasuhiko Kano · Tetsuro Kodama

Received: 7 July 2006 / Accepted: 14 September 2006 / Published online: 10 November 2006
© Springer-Verlag 2006

Abstract

Purpose We evaluated the tolerability and activity of the combination of weekly paclitaxel (PTX) and gemcitabine (GEM) in second-line treatment of advanced non-small cell lung cancer (NSCLC) after treatment with platinum-based chemotherapy.

Patients and methods PTX (100 mg/m²) and GEM (1,000 mg/m²) were administered to patients with previous treated NSCLC on days 1 and 8 every 3 weeks.

Results A total of 40 patients (performance status 0/1/2, 7/27/6 pts) were enrolled. The response rate was 32.5% (95% confidence interval: 18.0–47.0%). The median survival time was 41.7 weeks (95% confidence interval: 28.5–54.7 weeks). The median time to disease progression was 19 weeks. Hematological toxicities (grade 3 or 4) observed included neutropenia in 60%, anemia in 15%, and thrombocytopenia in 12.5% of patients. Non-hematological toxicities were mild, with the exception of grade 3 diarrhea, pneumonitis, and

rash in one patient each. There were no deaths due to toxicity.

Conclusion The combination of weekly PTX and GEM is a feasible, well-tolerated, and active means of second-line treatment of advanced NSCLC.

Keywords Non-small cell lung cancer · Second-line chemotherapy · Weekly chemotherapy · Gemcitabine · Paclitaxel

Introduction

The clinical usefulness of second-line chemotherapy has been established for cases of advanced non-small cell lung cancer (NSCLC) in which tumor has recurred or exhibits resistance to treatment after first-line chemotherapy. The effectiveness of docetaxel, pemetrexed, and erlotinib for second-line chemotherapy for NSCLC has been demonstrated in phase III clinical studies [13, 23, 24]. Furthermore, paclitaxel (PTX) and gemcitabine (GEM) have been shown to be effective against NSCLC resistant to platinum preparations [5, 16, 20]. There appears to be partial non-cross-resistance between these drugs and platinum preparations.

In previous attempts at second-line chemotherapy for NSCLC, the response rate was 0–38% for patients treated with PTX alone at intervals of 3 weeks [12, 21, 25] and 8–37.5% for patients treated with low-dose weekly PTX therapy [5, 16, 26, 28]. On the other hand, the rate of response to uncombined GEM therapy was 6–21% [7, 11, 17, 20, 22].

In combined PTX and GEM therapy, the two drugs exhibit interactions with each other but no overlap or synergism of adverse reactions. When this combined

K. Mori (✉) · Y. Kamiyama · T. Kondo · Y. Kano ·
T. Kodama

Department of Thoracic Diseases, Tochigi Cancer Center,
4-9-13, Yonan, Utsunomiya, Tochigi 320-0834, Japan
e-mail: kmori@tcc.pref.tochigi.jp

Y. Kamiyama
e-mail: ykamiyam@tcc.pref.tochigi.jp

T. Kondo
e-mail: tkondo@tcc.pref.tochigi.jp

Y. Kano
e-mail: ykano@tcc.pref.tochigi.jp

T. Kodama
e-mail: tkodama@tcc.pref.tochigi.jp

regimen was applied to previously untreated patients with NSCLC, the response rate was high, at 29–46% [1, 3, 4, 8, 15, 18]. When a combination of PTX (administered every 3 weeks) and GEM was used for second-line chemotherapy, the response rate was either 18 or 39% [2, 14].

Weekly chemotherapy for lung cancer has recently been attempted at several facilities [3, 9]. Favorable results of weekly chemotherapy have also been reported for recurrent NSCLC [5, 16, 26, 28]. Compared to standard regimens of chemotherapy, with administration of drugs at intervals of 3–4 weeks, weekly chemotherapy has certain advantages. For example, the single dose level of anti-cancer drugs can be reduced with weekly chemotherapy, and the dose level can be adjusted after the start of treatment depending on signs of hematological toxicity of the drugs or the general condition of individual patients. In comparison with treatment at intervals of 3–4 weeks, weekly chemotherapy was of equal efficacy but had fewer side effects [3]. Weekly chemotherapy is thus a promising means of treating cases of recurrent NSCLC in which bone marrow function has been compromised by first-line chemotherapy.

The present study was undertaken to evaluate the effectiveness and safety of weekly chemotherapy using a combination of PTX and GEM in cases of advanced NSCLC in which tumor had recurred or relapsed after platinum-based first-line chemotherapy or platinum-based first-line chemotherapy had failed to exert efficacy.

Patients and methods

Patient selection

Patients were required to have histologically or cytologically confirmed non-resectable or metastatic NSCLC that had progressed during or after one or more chemotherapy regimens. The trial was initiated after a rest period of at least 4 weeks following previous chemotherapy (2 weeks in the case of radiotherapy). Patients were required to have recovered completely from prior therapy, and to have no ongoing toxicity greater than grade 1. Other eligibility criteria were as follows: measurable lesions; life expectancy of at least 12 weeks; Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 ; adequate bone marrow reserve (defined as absolute granulocyte count $\geq 2,000/\text{ml}$ and platelet count $\geq 100,000/\text{ml}$); adequate hepatic and renal function (defined as serum creatinine level $\leq 2 \text{ mg/dl}$, AST and ALT ≤ 1.5 times

the upper limit of normal, and bilirubin $\leq 1.5 \text{ mg/dl}$). Exclusion criteria included pre-existing motor or sensory neurological signs or symptoms \geq grade 2 (Common Terminology Criteria for Adverse Events version 3.0) and active infections. Asymptomatic treated or untreated patients with brain metastases were not excluded from the study. The Ethics Committee of the Tochigi Cancer Center approved the study protocols. Written informed consent was obtained from every patient stating that the patient was aware of the investigational nature of this treatment regimen.

Treatment

Paclitaxel was administered at a dose of 100 mg/m^2 intravenously during a 1-h infusion on days 1 and 8 of the treatment cycle. Gemcitabine was administered at a dose of $1,000 \text{ mg/m}^2$ intravenously during a 30-min infusion on days 1 and 8 of the treatment cycle. Prior to each treatment, patients were given diphenhydramine 50 mg orally, and an H2 blocker intravenously along with dexamethasone 16 mg 30 min before PTX administration. Granisetron 3 mg was administered intravenously as an antiemetic. The length of each chemotherapy cycle was 21 days. Patients who experienced grade 4 leukopenia or neutropenia that lasted for 3 or more days, or who experienced grade 4 thrombocytopenia or reversible grade 2 neurotoxicity or liver dysfunction, received reduced doses of both PTX and GEM (PTX 80 mg/m^2 , GEM 800 mg/m^2) for the next cycle. If non-hematological toxicities of grade 3 or higher occurred, treatment was stopped. Subsequent courses of chemotherapy were started after 3 weeks when the leukocyte count was $3,000/\text{mm}^3$ or more, the neutrophil count was $1,500/\text{mm}^3$ or more, the platelet count was $75,000/\text{mm}^3$ or more, serum creatinine were less than 1.5 mg/dl , GOT and GPT were less than twice the upper limit of the normal range, and neurotoxicity was grade 1 or less. If these variables did not return to adequate levels by the first day of the next course of chemotherapy, treatment was withheld until full recovery. If more than 6 weeks passed from the time of the last treatment before these criteria were met or if change in treatment more significant than reduction of dose was indicated, the patient was removed from the study at that time, but still included in the analysis of its results.

Evaluation of responses and toxicity

Pretreatment evaluation included medical history, physical examination, complete blood count, bone marrow examination, serum biochemical analyses,

chest roentgenogram, electrocardiogram, and urinalysis. All patients underwent radionuclide bone scan, magnetic resonance or computerized tomography (CT) of the brain, and CT of the thorax and abdomen. Complete blood count, biochemical tests, serum electrolytes, urinalysis, and chest roentgenograms were obtained before patients received chemotherapy.

Responses and toxicity were evaluated on the basis of tumor images obtained by CT and other techniques, laboratory data, and subjective/objective symptoms and signs before, during, and after administration of the study drugs and during the period from completion of treatment to final analysis. Measurable disease parameters were determined every 4 weeks by various means such as computerized tomography. Evaluation was performed in compliance with the Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for antitumor activity and with Common Terminology Criteria for Adverse Events version 3.0 for safety. Patients were withdrawn from the study if evidence of tumor progression was obtained. The Institutional Ethical Review Committee gave approval to the study.

The primary endpoint of the study was the response rate. Simon's two-stage optimum design was used to determine sample size and decision criteria. It was assumed that a response rate of 30% among eligible patients would indicate potential usefulness while a rate of 10% would be the lower limit of interest, with $\alpha = 0.05$ and $\beta = 0.10$. Using these design parameters, the first stage of the study was initially to enroll 18 patients, and this regimen was to be rejected if fewer than two patients had an objective response. If two or more patients responded, accrual was to be continued to 36 patients. Considering the percentage of probable dropout cases, 40 patients were required. Secondary endpoints were toxicity and overall survival. Response and survival rates were both calculated on an intent-to-treat basis. Overall survival and time to progression were measured from the start of this treatment up to the time of death or up to the date of the last follow-up clinical assessment. Survival curves were constructed using the Kaplan–Meier method.

Results

Patient characteristics

Forty patients were enrolled in this study from October 2000 to July 2003. All patients were assessable for toxicity, response, and survival. Characteristics of the 40 patients are listed in Table 1. All 40 patients had




Fig. 1 Kaplan–Meier estimated overall survival curves. Median survival time, 41.7 weeks; 1-year survival rate, 38%

received a prior platinum-based chemotherapy regimen (Table 1). Two of these patients had received more than one chemotherapy regimen. All 40 patients were eligible for toxicity assessment. Four patients had received prior chemotherapy in the neoadjuvant setting. Of the 40 patients, 15 had initially responded to platinum-based therapy, 24 patients had achieved stable disease (SD), and one had progressive disease (PD).

Efficacy of treatment

The mean number of cycles administered per patient was 4, and number of cycles ranged from one to twelve. Three patients required reduction of dose due to neutropenia and thrombocytopenia. Thirteen patients exhibited partial response (PR). Overall response rate was 32.5% (13/40) [95% confidence interval (CI): 18–47%]. SD was achieved in 26 patients (65%), and one (2%) achieved PD. All 40 patients were included in the survival analysis, with a median follow-up time of 82.9 weeks (range 56–263 weeks). The overall median survival time was 41.7 weeks (95% CI: 28.5–54.7 weeks). The 1-year survival rate was 37.5% (15/40) (Fig. 1). The median time to disease progression was 19 weeks.

Toxicities (Table 2)

Table 2 lists toxicities observed during this study. Hematological toxicities included high incidences of leukopenia and neutropenia, with leukopenia and neutropenia of grade 3 or higher occurring in 45 and 60% of patients, respectively. Anemia and thrombocytopenia of grade 3 or higher occurred in 15 and 12.5% of patients, respectively. Non-hematological toxicities

Table 1 Patient characteristics

Eligible patients	40
Gender	
Male	27
Female	13
Age (years)	
Median	59
Range	33–75
Performance status	
0	7
1	27
2	6
Histology	
Adenocarcinoma	30
Squamous cell	8
Large cell	2
Stage III	10
Stage IV	30
Number of metastatic sites	
Median	2
Range	0–3
Location of metastases	
Bone	13
Lung nodules	12
Brain	10
Lymph nodes	7
Liver	5
Adrenals	3
Subcutaneous	1
Prior surgery	4
Prior irradiation	15
Lung only	9
Brain only	4
Lung and bone	2
Prior chemotherapy	40
Cisplatin/vinorelbine	32
Cisplatin/docetaxel	5
Cisplatin/irinotecan	3
Response to prior chemotherapy	
Partial response	15
Stable disease	24
Progressive disease	1

observed included grade 3 pneumonitis in one patient, who exhibited rapid recovery following administration of steroids, grade 3 diarrhea in one, and grade 3 rash in one. Other non-hematological toxicities observed were of grade 2 or less and included nausea in 47.5%, vomiting in 20%, alopecia in 45%, sensory neuropathy in 35%, and fatigue in 32.5% of patients. All of these toxicities disappeared or were improved by symptomatic treatment. There were no deaths due to toxicity.

Discussion

Although a standard regimen of chemotherapy for recurrent NSCLC is being established, it is still important to determine how the outcome of treatment of this cancer

can be improved [13, 23, 24]. At this point, the results of large-scale phase III clinical trials indicate single-agent chemotherapy with docetaxel, erlotinib, or pemetrexed as the standard chemotherapy regimen for recurrent NSCLC. In recent years, however, many reports have been published investigating two-drug combined therapy rather than single-agent therapy for recurrent NSCLC, with the objective of further improving therapeutic outcomes [2, 5, 7, 11–14, 20–26, 28].

A large number of reports have been published concerning salvage chemotherapy for recurrent NSCLC. Platinum-based chemotherapy is now used as the first-line chemotherapy at most medical facilities. Reports on second-line chemotherapy for NSCLC published to date have principally concerned uncombined drug therapy or two-drug combined therapy using non-platinum preparations [2, 5, 7, 11, 12, 14, 16, 17, 20–22, 25, 26, 28]. At several facilities, weekly administration chemotherapy has been adopted [5, 16, 26, 28]. Weekly-administration chemotherapy allows single dose levels to be reduced, thus making it possible to adjust the dose levels of anti-cancer agents after the start of treatment depending on adverse reactions or the general condition of individual patients.

Table 3 summarizes the results of two-drug combined therapy for recurrent NSCLC using non-platinum preparations [2, 6, 9, 10, 14, 19, 27]. The studies shown in this table were phase I-II in the case of that reported by Iaffaioli [14], phase III in that by Fossella [9], and phase II in the other studies. The overall response rate varied widely among studies, from 0.8 to 39%. The overall median survival time was 24–47 weeks and the one-year survival rate was 19–46%. Major adverse reactions observed in these studies were signs of hematological toxicity (particularly neutropenia), excluding the studies involving prophylactic G-CSF treatment reported by Androulakis [2] and Wachters [27]. Signs of non-hematological toxicity varied depending on the drugs used, and symptoms and signs unique to each drug were noted.

For combined PTX and GEM therapy for recurrent NSCLC, Androulakis [2] reported an overall response rate of 18%, an overall median survival time of 47 weeks, and a median time to disease progression of 34 weeks. Compared to the present study, the overall response rate reported by Androulakis was lower, while the overall median survival time and median time to disease progression were more favorable in the study by Androulakis. The dosing regimen used by Androulakis involved administration of PTX (175 mg/m²; day 8), GEM (900 mg/m²; days 1 and 8), and granulocyte colony-stimulating factor (G-CSF; days

Table 2 Maximum toxicity over 152 cycles (40 patients)

	CTCAE v 3.0 grade (number of patients)					Grade 3 ≤ (%)
	0	1	2	3	4	
Leukopenia	7	4	11	15	3	18 (45)
Neutropenia	6	5	5	17	7	24 (60)
Febrile neutropenia	–	–	–	2	–	2 (5)
Anemia	4	8	22	5	1	6 (15)
Thrombocytopenia	9	21	5	3	2	5 (12.5)
Pneumonitis	36	1	0	1	0	1 (2.5)
Diarrhea	27	9	3	1	0	1 (2.5)
Rash	22	15	2	1	0	1 (2.5)
Nausea	21	19	0	0	0	
Vomiting	32	3	5	0	0	
Fatigue	27	11	2	0	0	
Alopecia	22	17	1	0	0	
Neuropathy-sensory	26	14	0	0	0	
Edema	32	8	0	0	0	
Arthralgia	33	7	0	0	0	

CTCAE v 3.0 Common terminology criteria for adverse events version 3.0

Table 3 Non-platinum regimens used as second-line treatment of non-small cell lung cancer

First author (Ref.)	No. of patients	Regimen and schedule	Response rate (%)	Survival	
				Median (weeks)	1-year (%)
Androulakis [2]	49	P 175 mg/m ² d 8 q 3w	18	47	37
		G 900 mg/m ² d 1,8 q 3w			
		G-CSF 150 µg/m ² d 9–15			
Iaffaioli [14]	37	P 90–240 mg/m ² d 1 q 3w	39	40	46
		G 1,000 mg/m ² d 1,8 q 3w			
Fossella [9]	123	FO 2 g/m ² /day d 1–3 q 3w	0.8	24	19
		V 30 mg/m ² d 1,8,15 q 3w			
Kosmas [19]	43	D 100 mg/m ² d 8 q 3w	33	36	28
		G 1,000 mg/m ² d 1,8 q 3w			
Cao [6]	33	CPT11 300 mg/m ² d 1 q 4w	9	25	23
		V 30 mg/m ² d 1,14 q 4w			
Georgoulas [10]	76	CPT11 300 mg/m ² d 8 q 3w	18.4	38	24.5
		G 1,000 mg/m ² d 1,8 q 3w			
Wachters [27]	52	CPT11 200 mg/m ² d 1 q 3w	10	27	30
		D 60 mg/m ² d 1 q 3w			
		G-CSF 150 µg/m ² d 2–12			
Present study	40	P 100 mg/m ² d 1,8 q 3w	32.5	42	38
		G 1,000 mg/m ² d 1,8 q 3w			

P paclitaxel, G gem citabine, FO infostamide, V vinorebine, D docetaxel, CPT-11 irinotecan, G-CSF granulocyte colony-stimulating factor, d day, q every

9–15), with each cycle of treatment lasting for 3 weeks. Because their regimen involved prophylactic administration of G-CSF, the incidence of grade 3 or worse neutropenia was lower than that in the present study (12 vs. 60%). However, the incidence of grade 2 or worse fatigue (a sign of non-hematological toxicity) was lower in the present study (4%) than in that reported by Androulakis (51%).

Belani [19] reported the results obtained with combined use of PTX and GEM as first-line chemotherapy

for NSCLC. In their study, PTX was administered using two regimens and a comparison was made between treatment with PTX on day 1 (200 mg/m²) and weekly treatment with PTX on days 1 and 8 (100 mg/m²/dose; identical to the regimen used in the present study). According to their report, the response rate was 45% for the first regimen and 46% for the second regimen, the median survival time was 42 and 39 weeks and the 1-year survival rate 46 and 41% for the first and second regimens, respectively. Efficacy thus did not differ

significantly between the two regimens. Signs of hematological toxicity were the major adverse reactions observed following treatment with both regimens. The incidences of neutropenia and alopecia were lower with the weekly regimen. On the basis of these results, Belani concluded that weekly PTX treatment combined with GEM is also useful as first-line chemotherapy for NSCLC.

In conclusion, weekly chemotherapy with PTX and GEM is a tolerable and active regimen for patients with advanced NSCLC previously treated with platinum-containing chemotherapy regimens. It should be recommended as a candidate regimen in planning a phase III clinical study of NSCLC previously treated with platinum-containing chemotherapy, and will ultimately be evaluated in a phase III clinical study.

Acknowledgments This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare (Tokyo, Japan), and by the second-term comprehensive 10-year strategy for cancer control.

References

1. Aguiar D, Aguiar J, Bohn U (2005) Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small cell lung cancer. *Cancer Chemother Pharmacol* 55:152–158
2. Androulakis N, Kouroussis C, Kakolyris S, Tzannes S, Papadakis E, Papadimitriou C, Geroyianni A, Georgopoulou T, Dimopoulou I, Souglakos J, Kotsakis A, Vardakis N, Hatzidaki D, Georgoulis V (1998) Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. *Ann Oncol* 9:1127–1130
3. Belani CP, Dakhil SR, Waterhouse D, Desch C, Rooney D, Clark R, Jorge J (2002) A randomized phase II trial of gemcitabine (G) plus paclitaxel (P) vs gemcitabine plus weekly paclitaxel in the treatment of non-small cell lung cancer (NSCLC). *Proc Am Soc Oncol* 21:312A
4. Bhatia S, Hanna N, Ansari R, Pletcher W, Einhorn L, Ng E, Sandler A (2002) A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. *Lung Cancer* 38:73–77
5. Buccheri G, Ferrigno D. (2004) Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin. *Lung Cancer* 45:227–236
6. Cao MG, Aramendia JM, Salgado E et al (2002) Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer. A phase II study. *Am J Clin Oncol* 25:480–484
7. Crino L, Mosconi AM, Scagliotti G et al (1999) Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. *J Clin Oncol* 17:2081–2085
8. Douillard JY, Lerouge D, Monnier A et al (2001) Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. *Br J Cancer* 84:1179–1184
9. Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. *J Clin Oncol* 18:2354–2362
10. Georgoulis V, Kouroussis C, Agelidou A et al (2004) Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomized, phase II study. *Br J Cancer* 91:482–488
11. Gillenwater HH, Tynan M, Natoli S et al (2000) Second-line gemcitabine in refractory stage IV non-small cell lung cancer: a phase II trial. *Clin Lung Cancer* 2:133–138
12. Hainsworth JD, Thompson DS, Greco FA et al (1995) Paclitaxel by 1-h infusion: an active drug in metastatic non-small cell lung cancer. *J Clin Oncol* 13:1604–1614
13. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. *J Clin Oncol* 22:1589–1597
14. Iaffaioli RV, Tortorello A, Gravina A et al (2000) Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer. *Lung Cancer* 30:203–210
15. Isla D, Rosell R, Sanchez JJ et al (2001) Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small cell lung cancer. *J Clin Oncol* 19:1071–1077
16. Juan O, Albert A, Ordone F et al (2002) Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. *Jpn J Clin Oncol* 32:449–454
17. Kooten MV, Traine G, Cinat G et al (1999) Single-agent gemcitabine in pretreated patients with non-small cell lung cancer: results of an Argentinean multicentre phase II trial. *Br J Cancer* 81:846–849
18. Kosmidis P, Mylonakis N, Dimopoulos A et al (2000) Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. *Semin Oncol* 27:3–8
19. Kosmas C, Tsavaris N, Vadiaka M et al (2001) Gemcitabine and docetaxel as second-line chemotherapy for patients with non-small cell lung carcinoma who failed prior paclitaxel plus platinum-based regimens. *Cancer* 92:2902–2910
20. Lara PN, Gumerlock PH, Mack PC et al (2004) Gemcitabine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: a phase II California Cancer Consortium Trial. *Clin Lung Cancer* 6:102–107
21. Nauman C, DeLaney TF, Park J et al (1997) Paclitaxel (Taxol) as a single agent salvage therapy in non-small cell lung cancer (NSCLC). *Proc Am Soc Clin Oncol* 16:476A
22. Sculier JP, Lafitte JJ, Berghmans T et al (2000) A phase II trial testing gemcitabine as second-line chemotherapy for non-small cell lung cancer. *Lung Cancer* 29:67–73
23. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol* 18:2095–2103
24. Shepherd FA, Pereira JR, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. *N Engl J Med* 53:123–132